Invesaro

Stocks Comparison

Bruker vs 10x Genomics: revenue, profit, margins and growth compared

Bruker brought in $3.4B of revenue in fiscal 2025, 10x Genomics $642.8M in fiscal 2025. Revenue changed by +2.1% at Bruker and +5.2% at 10x Genomics on the year before, so 10x Genomics grew faster. Bruker kept -0.3% of its revenue as net profit, 10x Genomics -6.8%. Free cash flow was $43.3M at Bruker and $130.1M at 10x Genomics.

Side by side, latest fiscal year

BRKRPTXG
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$3.4B$642.8M
Revenue growth+2.1%+5.2%
Net income-$8.6M-$43.5M
Net margin-0.3%-6.8%
Free cash flow$43.3M$130.1M
Free cash flow margin1.3%20.2%
Earnings per share (diluted)-$0.15-$0.35
Cash$298.8M$474M
Debt$1.9Bn/a
Price to earningsn/an/a
Market value$71.7B$11.2B
Dividend yieldn/an/a
Rank by revenue in sector#163 of 451 · Industrials#299 of 451 · Industrials

Over the years

Revenue
BRKRP FY2018: $1.9BBRKRP FY2019: $2.1BBRKRP FY2020: $2BBRKRP FY2021: $2.4BBRKRP FY2022: $2.5BBRKRP FY2023: $3BBRKRP FY2024: $3.4BBRKRP FY2025: $3.4BTXG FY2019: $146.3MTXG FY2019: $245.9MTXG FY2020: $298.8MTXG FY2021: $490.5MTXG FY2022: $516.4MTXG FY2023: $618.7MTXG FY2024: $610.8MTXG FY2025: $642.8MFY18FY19FY20FY21FY22FY23FY24FY25
BRKRP $3.4BTXG $642.8M
Net income
BRKRP FY2018: $179.7MBRKRP FY2019: $197.2MBRKRP FY2020: $157.8MBRKRP FY2021: $277.1MBRKRP FY2022: $296.6MBRKRP FY2023: $427.2MBRKRP FY2024: $113.1MBRKRP FY2025: -$8.6MTXG FY2019: -$112.5MTXG FY2019: -$31.3MTXG FY2020: -$542.7MTXG FY2021: -$58.2MTXG FY2022: -$166MTXG FY2023: -$255.1MTXG FY2024: -$182.6MTXG FY2025: -$43.5MFY18FY19FY20FY21FY22FY23FY24FY25
BRKRP -$8.6MTXG -$43.5M
Net margin
BRKRP FY2018: 9.5%BRKRP FY2019: 9.5%BRKRP FY2020: 7.9%BRKRP FY2021: 11.5%BRKRP FY2022: 11.7%BRKRP FY2023: 14.4%BRKRP FY2024: 3.4%BRKRP FY2025: -0.3%TXG FY2019: -76.9%TXG FY2019: -12.7%TXG FY2020: -181.6%TXG FY2021: -11.9%TXG FY2022: -32.1%TXG FY2023: -41.2%TXG FY2024: -29.9%TXG FY2025: -6.8%FY18FY19FY20FY21FY22FY23FY24FY25
BRKRP -0.3%TXG -6.8%
Revenue growth
BRKRP FY2019: +9.3%BRKRP FY2020: -4.1%BRKRP FY2021: +21.7%BRKRP FY2022: +4.7%BRKRP FY2023: +17.1%BRKRP FY2024: +13.6%BRKRP FY2025: +2.1%TXG FY2019: +68.1%TXG FY2020: +21.5%TXG FY2021: +64.1%TXG FY2022: +5.3%TXG FY2023: +19.8%TXG FY2024: -1.3%TXG FY2025: +5.2%FY19FY20FY21FY22FY23FY24FY25
BRKRP +2.1%TXG +5.2%
Free cash flow
BRKRP FY2018: $190.5MBRKRP FY2019: $140.4MBRKRP FY2020: $235MBRKRP FY2021: $190.4MBRKRP FY2022: $145.2MBRKRP FY2023: $243.2MBRKRP FY2024: $136MBRKRP FY2025: $43.3MTXG FY2019: -$82.7MTXG FY2019: -$8.1MTXG FY2020: -$254.6MTXG FY2021: -$122.7MTXG FY2022: -$165.3MTXG FY2023: -$63.8MTXG FY2024: -$5.7MTXG FY2025: $130.1MFY18FY19FY20FY21FY22FY23FY24FY25
BRKRP $43.3MTXG $130.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about Bruker and 10x Genomics

Which is bigger by revenue, Bruker or 10x Genomics?

Bruker is bigger by revenue: $3.4B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.

Which keeps more of its revenue as profit, Bruker or 10x Genomics?

Bruker had a net margin of -0.3% in fiscal 2025; 10x Genomics had -6.8% in fiscal 2025.

Which grew revenue faster, Bruker or 10x Genomics?

In their latest fiscal years revenue changed by +2.1% at Bruker and +5.2% at 10x Genomics.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies